<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-317 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-317</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-317</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-278250194</p>
                <p><strong>Paper Title:</strong> Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies</p>
                <p><strong>Paper Abstract:</strong> Simple Summary The prognosis of non-small cell lung cancer with common EGFR mutations remains poor, despite the results obtained with the introduction of tyrosine kinase inhibitors. Disease progression during targeted therapy is linked to the development of resistance mechanisms. This literature review aims to summarize and clarify the main therapeutic strategies developed to address this important unmet medical need, including the latest updated and recently presented data.</p>
                <p><strong>Cost:</strong> 0.012</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e317.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e317.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR prevalence (Asian vs Caucasian)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prevalence of EGFR-activating mutations in Asian versus Caucasian NSCLC populations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper states that EGFR-activating mutations occur markedly more often in Asian patients than in Caucasian patients, citing ~50% incidence in Asian non-squamous NSCLC versus 10-15% in the Caucasian non-squamous NSCLC population; these mutations are also associated with non-smokers, younger age, and female sex.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asian; Caucasian</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Asian population vs Caucasian population (general/global)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Caucasian (non-squamous NSCLC): 10-15%; Asian (non-squamous NSCLC): up to ~50%</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Common mutations: exon 19 deletions (del19) and L858R (exon 21) â‰ˆ 90% of EGFR mutations; uncommon mutations 5-10%; tertiary/resistance mutations (e.g., T790M, C797S) mentioned elsewhere</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Asian: up to ~50% (non-squamous NSCLC); Caucasian: 10-15% (non-squamous NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>EGFR mutations are usually found in non-smokers (paper notes higher incidence in non-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Higher incidence in female patients (paper notes higher incidence in females).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>Paper notes association with non-smoking but does not propose this as a mechanistic explanation for ethnic differences; no specific lifestyle explanations proposed for ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>No explicit explanatory mechanism for ethnic differences is proposed in the text; the paper reports the observed epidemiologic differences and associations (age, sex, smoking status) but does not attribute them to genetic, environmental, or detection-bias causes.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Non-squamous NSCLC / NSCLC (EGFR-mutated cases primarily discussed)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Common EGFR mutations (del19 and L858R) show marked sensitivity to EGFR TKIs; the paper does not provide ethnicity-specific differential response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e317.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e317.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR exon 20 insertions (ethnic note)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prevalence and characteristics of EGFR exon 20 insertion mutations (noted higher in Asian patients)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper reports that exon 20 insertion mutations account for 4-12% of EGFR-mutated NSCLC and are described especially in the Asian population and in non-smokers; these mutations have poor response to standard EGFR TKIs (response <10%).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Described especially in Asian patients (paper-level statement)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Asia / Asian populations (general statement)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Exon 20 insertions: 4-12% of EGFR-mutated NSCLC (paper reports this proportion among EGFR-mutated cases)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>EGFR exon 20 insertion mutations; other uncommon mutations noted: G719X (exon 18, ~3%), S768I (exon 20, ~1%), L861Q (exon 21, ~1%).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Described as occurring especially in the Asian population; no numeric comparative frequency (Asian vs non-Asian) provided for exon 20 insertions beyond the 4-12% figure among EGFR-mutant tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Described more commonly in non-smoker patients.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>No explicit explanation provided in the paper for the higher frequency in Asian patients; statement is observational.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>EGFR-mutated NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Poor response to conventional EGFR TKIs (paper states <10% response rate for exon 20 insertions).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Lung cancer in patients who have never smoked-An emerging disease. <em>(Rating: 2)</em></li>
                <li>Oncogeneaddicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <em>(Rating: 2)</em></li>
                <li>Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non-Small Cell Lung Cancer. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>